RG6129 / Roche - LARVOL DELTA

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov) - P1 | N=23 | Terminated | Sponsor: Hoffmann-La Roche | N=260 ➔ 23 | Trial completion date: Feb 2024 ➔ Jul 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Feb 2024 ➔ Jul 2023; The study was terminated due to program discontinuation.

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor • HLA-A • MAGEA4

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov) - P1 | N=260 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2026 ➔ Feb 2024 | Trial primary completion date: Oct 2026 ➔ Feb 2024

Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • HLA-A • MAGEA4

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov) - P1; N=260; Recruiting; Sponsor: Hoffmann-La Roche; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor • HLA-A • MAGEA4